TREATMENT WITH CYTOMEGALOVIRUS (CMV) PP65-SPECIFIC LYPHOCYTES IN PATIENTS WITH CMV REACTIVATION OR CMV DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION.
Recruiting
- Conditions
- CMV reactivationCMV diseaseCMV reactivatieCMV ziekte virusreactivatie
- Registration Number
- NL-OMON24017
- Lead Sponsor
- eiden University Mecical Center
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 15
Inclusion Criteria
1. Age 0-75 years;
2. Recipient of alloSCT for standard indication according to national- and European Group for blood and Marrow Transplantation-guidelines (see appendix D);
Exclusion Criteria
1. Life expectation < 3 months;
2. End stage irreversible multi-system organ failure;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The number of events of acute GvHD, death and all other adverse events.
- Secondary Outcome Measures
Name Time Method 1. The number of CMV-specific T cells at different time points after infusion of CMV pp65-specific T cells;<br /><br>2. The number of complete responses or partial responses of CMV reactivation or CMV disease after infusion of CMV pp65-specific T cells.